MedTrace Logo

Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer

NCT00004207 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2014-06-24

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of liposomal daunorubicin in treating patients who have metastatic breast cancer.

Conditions

Interventions

DRUG

liposomal daunorubicin citrate

Sponsors & Collaborators

  • University of Leicester

    lead OTHER

Principal Investigators

  • Kenneth O'Byrne, MD · University Hospitals, Leicester

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004207 on ClinicalTrials.gov